Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Post-trial Access Program: Idursulfase-IT (HGT-2310) in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment

TAK609 PTA

Phase: N/A
Clinicaltrials.gov ID: NCT05795361

What is the goal of the study?

This is a post trial access program to continue to allow continued study drug (intrathecal idursulfase) access for our Hunter Syndrome patients that were previously enrolled in the HGTHIT046 trial.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Christina Lam
Study Team Member: Hayden Vreugdenhil, [email protected]

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.